A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).

Trial Details

NCT ID

NCT05528055

Phase

PHASE1

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

SCR-6920 capsule

Locations (sample)

Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not toler…
At least one evaluable or measurable lesion (as defined in the protocol).
ECOG Performance Status 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →